The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns
The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.